Literature DB >> 14625300

Desensitization masks nanomolar potency of ATP for the P2X1 receptor.

Jürgen Rettinger1, Günther Schmalzing.   

Abstract

ATP-gated P2X1 receptors feature fast activation and fast desensitization combined with slow recovery from desensitized states. Here, we exploited a non-desensitizing P2X2/P2X1 chimera that includes the entire P2X1 ectodomain (Werner, P., Seward, E. P., Buell, G. N., and North, R. A. (1996) Proc. Natl. Acad. Sci. U. S. A. 93, 15485-15490) to obtain a macroscopic representation of intrinsic receptor kinetics without bias arising from the overlap of channel activation and desensitization. From the stationary currents made amenable to analysis by this chimera, an EC50 for ATP of 3.3 nM was derived, representing a >200- and >7000-fold higher ATP potency than observed for the parental P2X1 and P2X2A receptors, respectively. Also, other agonists activated the P2X2/P2X1 chimera with nanomolar EC50 values ranging from 3.5 to 73 nM in the following rank order: 2-methylthio-ATP, 2',3'-O-(4-benzoylbenzoyl)-ATP, alpha,beta-methylene-ATP, adenosine 5'-O-(3-thiotriphosphate). Upon washout, the P2X2/P2X1 chimera deactivated slowly with a time constant (ranging from 63 to 2.5 s) that is inversely related to the EC50 value for the corresponding agonist. This suggests that deactivation time courses reflect unbinding rates, which by themselves define agonist potencies. The P2X2/P2X1 chimera and the P2X1 receptor possess virtually identical sensitivity to inhibition by the P2X1 receptor-selective antagonist NF279, a suramin analog. These results suggest that the P2X1 ectodomain confers nanomolar ATP sensitivity, which, within the wild-type P2X1 receptor, is obscured by desensitization such that only a micromolar ATP potency can be deduced from peak current measurements, representing an amalgam of activation and desensitization.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14625300     DOI: 10.1074/jbc.M306987200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  30 in total

1.  Identification of ectodomain regions contributing to gating, deactivation, and resensitization of purinergic P2X receptors.

Authors:  Hana Zemkova; Mu-Lan He; Taka-aki Koshimizu; Stanko S Stojilkovic
Journal:  J Neurosci       Date:  2004-08-04       Impact factor: 6.167

2.  Quantal release of ATP from clusters of PC12 cells.

Authors:  Alessandra Fabbro; Andrei Skorinkin; Micaela Grandolfo; Andrea Nistri; Rashid Giniatullin
Journal:  J Physiol       Date:  2004-08-26       Impact factor: 5.182

Review 3.  Molecular and functional properties of P2X receptors--recent progress and persisting challenges.

Authors:  Karina Kaczmarek-Hájek; Eva Lörinczi; Ralf Hausmann; Annette Nicke
Journal:  Purinergic Signal       Date:  2012-05-01       Impact factor: 3.765

4.  Allosteric nature of P2X receptor activation probed by photoaffinity labelling.

Authors:  Y Bhargava; J Rettinger; A Mourot
Journal:  Br J Pharmacol       Date:  2012-11       Impact factor: 8.739

Review 5.  Pharmacology of P2X channels.

Authors:  Joel R Gever; Debra A Cockayne; Michael P Dillon; Geoffrey Burnstock; Anthony P D W Ford
Journal:  Pflugers Arch       Date:  2006-04-29       Impact factor: 3.657

6.  Invited Lectures : Overviews Purinergic signalling: past, present and future.

Authors: 
Journal:  Purinergic Signal       Date:  2006-05-15       Impact factor: 3.765

7.  Ligand-gated purinergic receptors regulate HIV-1 Tat and morphine related neurotoxicity in primary mouse striatal neuron-glia co-cultures.

Authors:  Mary E Sorrell; Kurt F Hauser
Journal:  J Neuroimmune Pharmacol       Date:  2013-10-25       Impact factor: 4.147

8.  Amino acid variations resulting in functional and nonfunctional zebrafish P2X(1) and P2X (5.1) receptors.

Authors:  Sean E Low; John Y Kuwada; Richard I Hume
Journal:  Purinergic Signal       Date:  2008-10-11       Impact factor: 3.765

9.  Identification of P2X(4) receptor transmembrane residues contributing to channel gating and interaction with ivermectin.

Authors:  Irena Jelínkova; Vojtech Vávra; Marie Jindrichova; Tomas Obsil; Hana W Zemkova; Hana Zemkova; Stanko S Stojilkovic
Journal:  Pflugers Arch       Date:  2008-04-22       Impact factor: 3.657

10.  Nucleoside triphosphate diphosphohydrolase-1 ectonucleotidase is required for normal vas deferens contraction and male fertility through maintaining P2X1 receptor function.

Authors:  Gilles Kauffenstein; Julie Pelletier; Elise G Lavoie; Filip Kukulski; Mireia Martín-Satué; Sébastien S Dufresne; Jérôme Frenette; Cristina Ribas Fürstenau; Michal J Sereda; Bertrand Toutain; Daniel Henrion; Robert Sullivan; Catherine Vial; Jean Sévigny
Journal:  J Biol Chem       Date:  2014-08-25       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.